The Wnt pathway has been recognized for its crucial role in human development and homeostasis, but its dysregulation has also been linked to several disorders, including cancer. Wnt signaling is crucial for the development and metastasis of several kinds of cancer. Moreover, members of the Wnt pathway have been proven to be effective biomarkers and promising cancer therapeutic targets. Abnormal stimulation of the Wnt signaling pathway has been linked to the initiation and advancement of cancer in both clinical research and in vitro investigations. A reduction in cancer incidence rate and an improvement in survival may result from targeting the Wnt/β-catenin pathway. As a result, blocking this pathway has been the focus of cancer research, and several candidates that can be targeted are currently being developed. Flavonoids derived from plants exhibit growth inhibitory, apoptotic, anti-angiogenic, and anti-migratory effects against various malignancies. Moreover, flavonoids influence different signaling pathways, including Wnt, to exert their anticancer effects. In this review, we comprehensively evaluate the influence of flavonoids on cancer development and metastasis by focusing on the Wnt/β-catenin signaling pathway, and we provide evidence of their impact on a number of molecular targets. Overall, this review will enhance our understanding of these natural products as Wnt pathway modulators.
Endometrial carcinoma is the most prevalent gynecologic cancer in industrialized countries and the second most common in developing countries after cervical cancer; it is the fourth most commonly diagnosed cancer. The purpose of this study is to evaluate the immunohistochemistry expression of oestrogen receptor (ER) and Her-2/neu in Sudanese patients with endometrial carcinoma (EMC). A retrospective descriptive study of archival formalin-fixed paraffin-embedded tissue from hysterectomy specimens acquired at Khartoum's Charity Teaching Hospital. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue samples from 40 patients with EMC. The immunohistochemistry method was used to examine the specimens for ER and Her2neu expression. SPSS was used to analyze the data, and the significance of the connection of these receptors' expression and histological grade of tumors was determined. In 30% of the cases, ER and Her-2/neu expressions were positive. Positive Her2neu expression was connected with the menopausal state (P-value ≤ 0.05), whereas ER was associated with Her2neu (P-value ≤ 0.05). The relationship between ER and Her2neu expression and histological grade and age in endometrial cancer was statistically insignificant. There is a statistically significant relationship between ER and Her2neu.
The objective of this paper was to evaluate the use of CD3, CD5, CD10, CD19, and CD20 markers in the differential identification of lymphoma subtypes. Methods and Results: This was a retrospective cross-sectional study included 82 patients with palpable lymphadenopathies. The formalin-fixed paraffin block sections immunostained with the Dako flex were investigated. CD3, CD5, CD10, CD19, and CD20 staining was performed on sections. The current study found that the two main types of lymphoma, Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, have a significant association with CD3, CD10, and CD19, and a highly significant association with CD20, implying that these CD markers are crucial for general classification and diagnosis of lymphoma. CD3 had a highly significant relationship with gender. CD3 and CD20 were demonstrated to have a significant relationship with the lymphoma subtypes. The CD20 marker is the most consistent and useful marker for differentiating lymphoma subtypes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.